Key facts
- Sonavex’s last known valuation is $45.0M.
- It has raised $24.1M across 4 recorded rounds; the latest was Early Stage VC ($15.0M) in Aug 2021.
- Notable investors include US National Science Foundation, MedTech Innovator, Gaingels, National Institutes of Health, Keiretsu Forum — 41 tracked in total.
- Sonavex has filed 7 Form Ds with the SEC since 2015, most recently Nov 2024 ($15.0M sold to 45 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 41 names
- ·Watchlist + deal alerts for Sonavex
Funding rounds
4 roundsAbout Sonavex
Developer of a bioresorbable and echogenic equipment technology designed to mark at-risk blood vessels. The company's technology collects arteriovenous fistula volumetric flow rate, diameter, and depth information at the dialysis clinic to support maturation assessment, such that the site can be easily assessed for future complications, enabling healthcare providers to determine blood flow and morphology of vessels and get actionable data to deliver patient care.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2013
- Employees
- 24
- Website
- sonavex.com/
- Ownership
- Privately Held (backing)
Sonavex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sonavex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sonavex in its N-PORT filings yet. We sweep new filings monthly.